epoxomicin,
L-threoninamide, N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-((1S)-3-methyl-1-(((2R)-2-methyl-2-oxiranyl)carbonyl)butyl)-,
N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-((1S)-3-methyl-1-(((2R)-2-methyl-2-oxiranyl)carbonyl)butyl)-L-threoninamide,
epoxomicin,
134381-21-8,
EPOXOMYCIN,
BU-4061T,
UNII-Y0900I3U8U,
BU 4061T,
CHEBI:42265,
Y0900I3U8U,
Y-100034,
C28H50N4O7,
SCHEMBL73907,
DTXSID5044073,
AMX10202,
BCP13740,
EX-A1663,
KS-00001D7W,
N-Acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-threoninamide,
N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-threoninamide,
ZINC3927842,
1756AH,
MFCD03791061,
Epoxomicin, >=95% (HPLC), solid,
CS-3998,
NCGC00485955-01,
HY-13821,
N-Acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-(3-methyl-1-((2-methyloxiranyl)carbonyl)butyl)-L-threoninamide,
(2R,3S)-2-[acetyl(methyl)amino]-N-[(2S,3S)-1-{[(2S,3R)-3-hydroxy-1-({(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}amino)-1-oxobutan-2-yl]amino}-3-methyl-1-oxopentan-2-yl]-3-methylpentanamide,
(2S,3S)-N-[(1S,2R)-2-hydroxy-1-{[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]carbamoyl}propyl]-3-methyl-2-[(2S,3S)-3-methyl-2-(N-methylacetamido)pentanamido]pentanamide,
CHEMBL207990,
C28-H50-N4-O7,
CID11226684,
A2606,
C078846,
Epoxomicin, 97%, a selective proteasome inhibitor - 1MG 1mg,
L-threoninamide, N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-((1S)-3-methyl-1-(((2R)-2-methyl-2-oxiranyl)carbonyl)butyl)-,
L-Threoninamide, N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-((1S)-3-methyl-1-(((2R)-2-methyloxiranyl)carbonyl)butyl)-,
N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-((1S)-3-methyl-1-(((2R)-2-methyl-2-oxiranyl)carbonyl)butyl)-L-threoninamide,